Is PDRN (Salmon DNA) the Real Deal? Grading Regenerative Buzz Ingredients with Science

TREND CHECK ／ KAIAN grades buzzwords with science

Marketed with catchy phrases like "salmon DNA" and "salmon-derived," PDRN (polydeoxyribonucleotide) and polynucleotides (PN) have surged in the past two or three years into headline buzzwords across social media and the Korean cosmetics market. Borrowing the aura of regenerative and aesthetic medicine, the names certainly sound effective. But is the evidence discussed for injections truly the same as the evidence for applying it topically as a cosmetic? In this trend check, we grade PDRN honestly — neither hyping nor dismissing it — by its mechanism and the strength of its evidence.

1. What PDRN actually is — fragments of DNA

PDRN is a highly purified mixture of DNA fragments extracted from sources such as the gonads (milt) of salmonid fish. Long DNA is enzymatically cut into oligo- and polynucleotides of roughly 50–2,000 base pairs. Because its sequence shares high homology with human DNA and it has low antigenicity (low likelihood of triggering allergic reaction), it has long been used in medicine. Polynucleotides (PN) are a closely related, higher-molecular-weight material, often discussed in the same breath but differing in molecular size and formulation design. The key point: PDRN is not a magical regenerative substance, but a supply source of nucleotides and a signaling molecule.

PDRN wears two faces. One is a "raw material of nucleotides" that cells can recycle for DNA synthesis. The other is a "signaling molecule" that changes cell behavior via a receptor. It is the latter that supposedly sets it apart from a mere humectant.

A related material, the single nucleotide cytidylic acid, is also used in cosmetics. Together, these "nucleic-acid-based" ingredients are drawing attention in the context of skin repair and conditioning.

2. Mechanism — the adenosine A2A receptor switch

PDRN's most distinctive mechanism is that adenosine generated from its breakdown stimulates the adenosine A2A receptor on cell surfaces. When the A2A receptor is activated, several phenomena have been reported at the research level. First, promotion of angiogenesis (formation of new capillaries) via vascular endothelial growth factor (VEGF) and others. Second, an anti-inflammatory effect that suppresses production of inflammatory cytokines such as TNF-α. Third, support of collagen production and tissue repair through fibroblast activation. In addition, the "salvage pathway" lets cells recycle supplied nucleotides for DNA and RNA synthesis, thought to further aid repair.

This multifaceted action has accumulated research in wound healing, ulcers, and tissue repair. But note that much of it comes from injection (subcutaneous or local administration), cultured cells, or animal models. Because the switch only flips once molecules "reach" the receptor, how it is delivered becomes decisively important.

3. Injection vs. topical — a fault line in the evidence

This is the heart of the trend check. The strong evidence for PDRN/PN derives overwhelmingly from injection — aesthetic-medicine skin-booster procedures and clinical local administration. Inject it directly into the skin and the molecules physically reach the dermal cells where A2A receptors reside. By contrast, when applied as a cosmetic on top of the stratum corneum, PDRN has a large molecular weight and high hydrophilicity, so it is scientifically reasonable to assume only a limited amount crosses a healthy skin barrier to reach dermal receptors.

The "tissue-repair and angiogenesis evidence shown by injection" cannot be told as-is as "the effect when applied as a cosmetic." This is a grading pitfall common not just to PDRN but to every regenerative-medicine-derived buzz ingredient.

There are reports that topical PDRN may contribute to skin conditioning through nucleotide supply, and to surface hydration and soothing. But overlaying the injection-derived story of "promoting angiogenesis" or "regenerating the dermis" onto a cosmetic is inappropriate, both under cosmetic-advertising law and from the standpoint of scientific honesty. KAIAN positions topical PDRN as a "promising nucleic-acid-based conditioning ingredient" and honestly distinguishes the strength of evidence.

4. Versus exosomes and growth factors — the delivery problem is shared

Alongside PDRN, the regenerative trend ingredients discussed on social media include exosomes, growth factors such as EGF and FGF, and human stem cell conditioned media. Each carries the alluring mechanism of cell-to-cell signaling, but they share one weakness: the wall of transdermal delivery. Growth factors are proteins, exosomes are lipid-bilayer vesicles, and PDRN is a large nucleic acid — all are large molecules, and there is scant guarantee they reach the dermis when applied.

• PDRN/PN: strong evidence by injection; topical is limited but promising as a nucleic-acid conditioning material.
• Growth factors (EGF/FGF): potent signals, but stability and transdermal delivery are challenges because they are proteins.
• Exosomes: theoretically attractive, but standardization and delivery evidence at the cosmetic level are still developing.

By contrast, soothing and repair ingredients designed to work at the skin surface — madecassoside, panthenol, CICA, beta-glucan, ectoine — have a strong match between site of action and delivery, and their cosmetic evidence keeps accumulating. "A flashy mechanism" and "realistic delivery" are different things: that is KAIAN's consistent view.

5. KAIAN's grade and practice — from a Skin Longevity view

From the standpoint of our brand philosophy, Skin Longevity (extending the functional lifespan of skin), PDRN can be graded thus. In the injection domain, "a repair/regeneration ingredient with thick clinical evidence." In the cosmetic domain, "a nucleic-acid conditioning ingredient whose mechanism is attractive but whose evidence for dermal delivery upon application is still developing." Put without hype, a B grade — not to be dismissed, but an ingredient requiring the calm not to carry the injection story into cosmetics.

Don't buy the buzzword; choose a formulation where site of action and delivery match. This is the shift from "choosing by feel" to "choosing by evidence."

There are three checkpoints in practice. First, judge by the formulation purpose (hydration, conditioning) and the whole formula, not by the words "salmon DNA." Second, stay cool toward advertising that conflates injection and topical evidence. Third, position next-generation ingredients like PDRN as an "addition" only after establishing the foundational barrier care — ceramides, sodium hyaluronate, niacinamide.

For the record, our own brand EVOLURE currently does not offer a PDRN-containing product. Rather than rushing to add it to chase a trend, we choose to wait until topical delivery and accumulated evidence are clear before bringing it to you. We do not dismiss trends — we grade them with the ruler of science. That is the KAIAN trend check.